Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;97(3):365-72.
doi: 10.1007/s11060-009-0041-z. Epub 2009 Nov 18.

Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells

Affiliations

Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells

Mathieu Provençal et al. J Neurooncol. 2010 May.

Abstract

The classical treatment scheme for medulloblastoma (MB) is based on a tri-therapy approach consisting of surgical tumor resection, craniospinal axis radiation and chemotherapy. With current treatments relying mainly on non-specific cytotoxic therapy, a better understanding of the mechanisms underlying resistance to these treatments is important in order to improve their effectiveness. In this study, we report that stimulation of DAOY with HGF resulted in the protection of these cells against etoposide-induced apoptosis, this anti-apoptotic effect being correlated with an increase in the expression of tissue factor (TF), the initiator of the extrinsic pathway of coagulation. HGF-mediated protection from apoptosis was abolished by a c-Met inhibitor as well as by siRNA-mediated reduction of TF levels, implying a central role of Met-dependent induction of TF expression in this process. Accordingly, stimulation of DAOY with FVIIa, the physiological ligand of TF, also resulted in a significant protection from etoposide-mediated cytotoxicity. Overall, our results suggest the participation of the haemostatic system to drug resistance in MB and may thus provide novel therapeutic approaches for the treatment of these tumors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nat Med. 2004 May;10(5):502-9 - PubMed
    1. Neuro Oncol. 2005 Oct;7(4):436-51 - PubMed
    1. Cancer Immunol Immunother. 2006 Nov;55(11):1301-8 - PubMed
    1. Am J Pathol. 2005 Apr;166(4):1153-62 - PubMed
    1. Oncogene. 1998 Jul 16;17(2):131-41 - PubMed

Publication types

MeSH terms

LinkOut - more resources